Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Cytokinetics Inc shares valued at $98,560 were sold by Malik Fady Ibraham on Sep 23 ’25. At $49.28 per share, Malik Fady Ibraham sold 2,000 shares. The insider’s holdings dropped to 140,610 shares worth approximately $6.79 million following the completion of this transaction.
Also, Blum Robert I sold 5,000 shares, netting a total of over 248,850 in proceeds. Following the sale of shares at $49.77 each, the insider now holds 373,108 shares.
Before that, Malik Fady Ibraham had sold 2,000 shares from its account. In a trade valued at $102,580, the EVP Research & Development traded Cytokinetics Inc shares for $51.29 each. Upon closing the transaction, the insider’s holdings decreased to 2,000 shares, worth approximately $6.79 million.
Analysts at Barclays started covering the stock with ‘”an Overweight”‘ outlook in a report released in late April. As of February 07, 2025, Citigroup has initiated its “Buy” rating for CYTK. Earlier on January 22, 2025, Stifel initiated its rating. Their recommendation was “a Buy” for CYTK stock.
Analyzing CYTK Stock Performance
On last trading session, Cytokinetics Inc [NASDAQ: CYTK] plunged -0.54% to $48.29. The stock’s lowest price that day was $47.73, but it reached a high of $49.33 in the same session. During the last five days, there has been a surge of approximately 1.53%. Over the course of the year, Cytokinetics Inc shares have dropped approximately -10.19%. Shares of the company reached a 52-week high of $54.22 on 09/08/25 and a 52-week low of $29.31 on 05/15/25.
Support And Resistance Levels for Cytokinetics Inc (CYTK)
According to the 24-hour chart, there is a support level at 47.57, which, if violated, would cause prices to drop to 46.85. In the upper region, resistance lies at 49.17. The next price resistance is at 50.05. RSI (Relative Strength Index) is 56.81 on the 14-day chart, showing neutral technical sentiment.
Is Cytokinetics Inc subject to short interest?
Stocks of Cytokinetics Inc saw a sharp steep in short interest on 2025-08-29 dropping by -1.69 million shares to 13.83 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 15.52 million shares. A decline of -12.2% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.42 of the overall float, the days-to-cover ratio (short ratio) decline to 8.42.
Which companies own the most shares of Cytokinetics Inc (CYTK)?
In terms of Cytokinetics Inc share price expectations, FactSet research, analysts set an average price target of 80 in the next 12 months, up nearly 64.78% from the previous closing price of $48.55. Analysts anticipate Cytokinetics Inc stock to reach 96 by 2025, with the lowest price target being 71. In spite of this, 12 analysts ranked Cytokinetics Inc stock as Buy at the end of 2025. On November 08, 2024, RBC Capital Mkts assigned a price target of “an Outperform” to the stock and initiated coverage with a $80.
